Chronic Liver Disease: New Targets and Mechanisms

Emmanuela John Sima[1st], Shivani Sharma[2nd], Diksha Sharma[3rd], Anchal Dhawan[4th]

Corresponding author- Shivani Sharma

emma61john@gmail.com[1st], shivanivashist637@gmail.com[2nd], sharmadishu418@gmail.com[3rd], anchaldhawan92@gmail.com[4th]

University School of Pharmaceutical Sciences[1-4], Rayat Bahra University Mohali, Punjab[1-4]

Abstract

Chronic liver disease (CLD) is a major global health concern, characterized by persistent liver inflammation, fibrosis, and progressive dysfunction. Despite advancements in understanding the pathophysiology of liver diseases, the therapeutic options remain limited. Recent research has uncovered novel molecular pathways, signaling networks, and cellular mechanisms involved in the progression of CLD, offering potential new therapeutic targets. These mechanisms include immune dysregulation, hepatic stellate cell activation, alterations in gut-liver axis, and the role of non-coding RNAs in disease progression. Additionally, emerging targets such as fibrosis biomarkers, inflammatory cytokines, and cellular senescence pathways provide exciting opportunities for early intervention and personalized treatment strategies. This review highlights the latest discoveries in chronic liver disease research, emphasizing innovative molecular targets, their therapeutic potential, and the challenges in translating these findings into clinical practice. Understanding these mechanisms could pave the way for novel treatments that effectively halt or reverse the progression of chronic liver disease, ultimately improving patient outcomes and quality of life.

Mechanism

One of the leading causes of illness and mortality worldwide is chronic liver disease (CLD) Cirrhosis, a major cause of death, can result from chronic liver illnesses such as viral hepatitis, alcohol-related liver disease (ALD), and non-alcoholic steatohepatitis (NASH). Cirrhosis and end-stage liver disease result from the progressive decline in liver function brought on by the several causes of liver disease. Pathological hallmarks of cirrhosis include the deformation of hepatic architecture, the degradation and necrosis of hepatocytes, and the replacement of liver parenchyma by fibrotic tissues and regenerating nodules. Hepatitis, liver fibrosis, cirrhosis, and non-alcoholic fatty liver disease (NAFLD) are all part of the degenerative illness known as chronic liver disease (CLD). Since the liver is necessary for metabolism, detoxification, and protein synthesis, CLD is a serious illness that affects public health broadly. There are no effective treatments, indicating an unmet need. Chronic liver illnesses are largely caused by metabolic pathways, in which immune cells, hepatic stellate cells, and other cell types are essential.

STAGES OF LIVER



Figure no 1: Shows Stages of Liver

Metabolism of Liver

The study of metabolic alterations in cells and tissues that suggest potential routes for the emergence of liver illnesses has been made possible by the development of metabolomics technologies. TIPS, or transjugular intrahepatic portal shunt, is used to reduce portal hypertension when liver dysfunction is present. However, in cirrhosis patients, TIPS may be linked to increased fat mass and weight gain. Metabolomics investigations were conducted in peripheral and portal serum before and early after TIPS to learn how it impacts metabolic pathways that may result in increased fat formation. In addition to some lipid, they discovered
The primary metabolites impacted were those linked to liver function and the metabolic pathways of several amino acids. Furthermore, despite the fact that the results were not statistically significant, certain portal metabolites may be prospective prognostic biomarkers for a deterioration in liver function. Another study used metabolomics to examine how the Chinese patented drug Xuezhiping capsule affected fatty liver and hyperlipidemia in a hamster model fed a high-fat diet. It has been shown that Xuezhiping capsules reduced triglycerides, total cholesterol, and low-density lipoprotein cholesterol while raising high-density lipoprotein cholesterol levels and reducing lipid droplet accumulation in the liver of hamsters fed a high-fat diet. But the biochemical indicators of oxidative stress, which are typically linked to fatty liver disease, rose after taking Xuezhiping capsules.

Therefore, more research is necessary to fully evaluate the Xuezhiping capsule's helpful impact in fatty liver disease. Bile acid (BA) metabolism is another metabolic pathway implicated in fatty liver disease. Dysregulation of this pathway is linked to obesity, non-alcoholic fatty liver disease (NAFLD), and other metabolic disorders because the body uses the conversion of BAs as the primary means of removing cholesterol. Additionally, patients with NASH have higher total BA levels and altered composition in the hepatic-intestinal circulation. The aforementioned research shows that metabolism can cause liver dysfunction, and more research is required to completely comprehend the function of metabolic pathways and how they interact with one another in liver illnesses.

Non-alcoholic fatty liver disease

A public health hazard, NAFLD affects 30% of people worldwide. As the damage worsens, non-alcoholic steatohepatitis (NASH) may develop, followed by cirrhosis and hepatocellular cancer. The limited sensitivity of MRI and ultrasonography makes it challenging to diagnose NAFLD in its early stages. Consequently, establishing links

between co-morbidities and early stages of NAFLD can enhance the disease's diagnosis and prognosis. A favorable association between diabetic retinopathy and liver fibrosis has been documented using a publicly accessible database that includes a cohort of 11,000 patients. According to their findings, diabetic retinopathy may be used to predict the course of NAFLD. Describe the impact of BA on NASH-liver in relation to the later stages of the disease. Progression of cancer. Taurine deoxycholate (TDCA) and glucose deoxycholate (GDCA) have been demonstrated in both in vitro and in vivo investigations to activate hepatic stellate cells and cause liver cancer. The presence of macrophages also influences the advancement of NAFLD and liver cancer. This highlights the variety of macrophage subpopulations and functions as well as the complex roles these cells play in the development of illness.



Therapeutic strategies of Liver

Hepatocyte fat buildup encourages oxidative stress and inflammation in the liver. BA play a crucial role in the liver's lipid metabolism and fat buildup. The part that chronic liver disorders play in the disturbance of BA homeostasis. They provide an overview of the use of a number of medications that have been studied in clinical trials that lower BA levels by either preventing their synthesis or encouraging their excretion. Obeticholic acid, a BA receptor agonist, reduces hepatic steatosis, lipid absorption, and bile acid synthesis. Alternative treatments for liver illness include natural substances and dietary supplements like taurine and curcumin.
In fact, in a rat acute model of hepatotoxicity, these substances counteracted the oxidative stress in the liver. Curcumin also improved several clinical indicators and decreased liver fibrosis. Another example is examining the use of a well-liked Chinese supplement made with botanical ingredients to effectively treat hyperlipidemia, which lowers the

amount of lipids in the liver and serum. Targeting dysregulated immunological checkpoints or particular immune cell metabolism is another intriguing strategy to reduce chronic inflammation in the liver. The most prevalent immune cells in the liver, macrophages—including resident Kupffer cells and those generated from invading monocytes—are greatly elevated in response to injury. the functions of macrophages in liver cancer and NAFLD. They draw attention to treatment approaches that reduce inflammation by inhibiting the invasion of macrophages or stopping their activation and the production of inflammatory cytokines. All of these newly discovered therapeutic options may enhance liver disease care and results, enhancing patients' quality of life and, ideally, lowering the high prevalence rates.

Another example is examining the use of a well-liked Chinese supplement made with botanical ingredients to effectively treat hyperlipidemia, which lowers the amount of lipids in the liver and serum. Targeting dysregulated immunological checkpoints or particular immune cell metabolism is another intriguing strategy to reduce chronic inflammation in the liver. The most prevalent immune cells in the liver, macrophages—including resident Kupffer cells and those generated from invading monocytes—are greatly elevated in response to injury. the functions of macrophages in liver cancer and NAFLD.

Novel treatment targets and possible biomarkers have been identified as a result of recent developments in our understanding of the mechanisms behind chronic liver disease. Some of the main players and targets in the pathophysiology of chronic liver disease are listed below:

1. Inflammation and Immune System Dysregulation

- Chronic inflammation is a key driver of liver injury and fibrosis in CLD. Inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukins (IL-6, IL-1β), and transforming growth factor-beta (TGF-β), play a central role in promoting fibrosis and liver damage.
- **Target:** Inhibiting inflammatory pathways using drugs that block cytokine receptors or modulate immune cell activity (e.g., IL-1β inhibitors, TNF-α blockers).

2. Hepatic Stellate Cell (HSC) Activation

- In response to liver injury, HSCs are activated and differentiate into myofibroblasts, which secrete extracellular matrix components that contribute to fibrosis.
- **Target:** Blocking HSC activation and fibrogenesis could prevent or reverse liver fibrosis. Antifibrotic therapies targeting HSCs or their secreted mediators (e.g., TGF-β, α-SMA) are being explored.

3. Mitochondrial Dysfunction

- Mitochondria are critical in maintaining liver function. Dysfunction in mitochondrial biogenesis and dynamics, particularly in the context of metabolic diseases like NAFLD and non-alcoholic steatohepatitis (NASH), contributes to oxidative stress and inflammation.
- **Target:** Therapeutic strategies to restore mitochondrial function, reduce oxidative stress, or improve mitochondrial dynamics are under investigation, including the use of antioxidants or agents that modulate mitochondrial pathways.

4. Endoplasmic Reticulum (ER) Stress

- ER stress is a key feature in chronic liver disease and is linked to insulin resistance, inflammation, and fibrosis. It can result in the accumulation of misfolded proteins, leading to activation of the unfolded protein response (UPR).
- **Target:** Agents that mitigate ER stress and restore protein homeostasis, such as chemical chaperones, are being explored as potential treatments for CLD.

5. Gut-Liver Axis and Microbiome

- The gut microbiome plays a crucial role in liver disease progression. Dysbiosis, or an imbalance in the gut microbiota, can lead to the release of endotoxins, which activate inflammatory pathways in the liver, contributing to conditions like NAFLD and NASH.
- **Target:** Modulating the gut microbiota through prebiotics, probiotics, or antibiotics, or targeting gut-derived molecules like lipopolysaccharides (LPS), may offer a novel therapeutic approach.

6. Liver Regeneration and Stem Cells

- Liver regeneration is a unique characteristic of the organ, but in chronic liver diseases, the regenerative response is often impaired. Research on liver stem cells and their role in fibrosis resolution is ongoing.
- **Target:** Stem cell-based therapies or strategies to enhance liver regeneration and tissue repair are promising for treating advanced liver disease, particularly cirrhosis.

7. Fibrosis Reversal

- Fibrosis is the result of an imbalance between extracellular matrix production and degradation. Targeting the pathways that regulate extracellular matrix turnover is an important area of research.
- **Target:** Several antifibrotic agents are in clinical trials, including those targeting collagen synthesis (e.g., lysyl oxidase inhibitors) or matrix metalloproteinases (MMPs) that degrade the extracellular matrix.

8. Nuclear Receptors and Lipid Metabolism

- Nuclear receptors such as peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), and farnesoid X receptor (FXR) play crucial roles in regulating lipid metabolism and inflammation.
- **Target:** Activating or inhibiting these nuclear receptors may offer therapeutic strategies for treating metabolic liver diseases like NAFLD/NASH and biliary cirrhosis.

9. Genetic and Epigenetic Factors

- Genetic predisposition plays a significant role in the development of chronic liver disease. Variants in genes related to lipid metabolism, fibrosis, and immune responses (e.g., PNPLA3, TM6SF2) are associated with increased susceptibility.
- **Target:** Understanding genetic and epigenetic modifications can help identify biomarkers and personalized treatment options for chronic liver disease.

10. Non-invasive Biomarkers and Imaging

- Identifying non-invasive biomarkers for disease progression (e.g., liver stiffness measurements, serum markers like Cytokeratin-18 fragments) is crucial for diagnosing and monitoring CLD.
- **Target:** New biomarkers or imaging techniques could facilitate early detection and more accurate assessment of liver fibrosis, enabling personalized treatment.

11. Metabolic Reprogramming and the Role of Adipokines

- In diseases like NASH, lipid accumulation leads to metabolic dysfunction, oxidative stress, and inflammation. Adipokines, secreted by adipose tissue, influence liver inflammation and fibrosis.
- **Target:** Targeting pathways related to lipid metabolism or adipokines, such as leptin and adiponectin, may hold therapeutic potential.

12. Cell Death Pathways (Apoptosis, Necroptosis)

- Cell death plays an important role in the progression of liver disease. Apoptosis and necroptosis (programmed necrosis) contribute to tissue damage and inflammation in chronic liver diseases.
- **Target:** Drugs that inhibit cell death pathways, such as caspase inhibitors or necroptosis inhibitors, are being evaluated in clinical trials for chronic liver diseases.

Reference

1. Asrani, S. K., Devarbhavi, H., Eaton, J., and Kamath, P. S. (2019). Burden of Liver Diseases in the World. J. Hepatol. 70, 151–171. doi:10.1016/j.jhep.2018.09.014
2. Cai, Q., Gan, C., Tang, C., Wu, H., and Gao, J. (2021). Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. Front. Pharmacol. 12, 784591. doi:10.3389/fphar.2021.784591
3. Cheemerla, S., and Balakrishnan, M. (2021). Global Epidemiology of Chronic Liver Disease. Clin. Liver Dis. 17, 365–370. doi:10.1002/cld.1061
4. Cheemerla, S., and Balakrishnan, M. (2021). Global Epidemiology of Chronic Liver Disease. Clin. Liver Dis. 17, 365–370. doi:10.1002/cld.1061
5. Gao,J.,Wei,B.,DeAssuncao,T.M.,Liu,Z.,Hu,X.,Ibrahim,S.,etal.(2020).Hepatic Stellate Cell Autophagy Inhibits Extracellular Vesicle Release to Attenuate Liver Fibrosis. J. Hepatol. 73, 1144–1154. doi:10.1016/j.jhep.2020.04.044
6. Gao, J., Wei, B., Liu, M., Hirsova, P., Sehrawat, T. S., Cao, S., et al. (2021). Endothelial P300 Promotes Portal Hypertension and Hepatic Fibrosis through C-C Motif Chemokine Ligand 2-Mediated Angiocrine Signaling. Hepatology 73, 2468–2483. doi:10.1002/hep.31617
7. Gijbels, E., Pieters, A., De Muynck, K., Vinken, M., and Devisscher, L. (2021). Rodent ModelsofCholestatic Liver Disease: A Practical Guide for Translational Research. Liver Int. 41, 656–682. doi:10.1111/liv.14800
8. Kochanek, K. D., Xu, J., and Arias, E. (2020). Mortality in the United States, 2019. USA Government, 1–8.
9. Kostallari, E., Hirsova, P., Prasnicka, A., Verma, V. K., Yaqoob, U., Wongjarupong, N., et al. (2018). Hepatic Stellate Cell-Derived Platelet-Derived Growth Factor Receptor-Alpha-Enriched Extracellular Vesicles Promote Liver Fibrosis in Mice through SHP2. Hepatology 68, 333–348. doi:10.1002/hep.29803
10. Kostallari, E., Valainathan, S., Biquard, L., Shah, V. H., and Rautou, P.-E. (2021). Role of Extracellular Vesicles in Liver Diseases and Their Therapeutic Potential. Adv. Drug Deliv. Rev. 175, 113816. doi:10.1016/j.addr.2021.05.026
11. Lan, T., Qian, S., Tang, C., and Gao, J. (2022). Role of Immune Cells in Biliary Repair. Front. Immunol. 13, 866040. doi:10.3389/fimmu.2022.866040
12. Liu, C., Zhou, B., Meng, M., Zhao, W., Wang, D., Yuan, Y., et al. (2021). FOXA3 Induction under Endoplasmic Reticulum Stress Contributes to Non-alcoholic Fatty Liver Disease. J. Hepatol. 75, 150–162. doi:10.1016/j.jhep.2021.01.042
13. Maiers, J. L., Kostallari, E., Mushref, M., Deassuncao, T. M., Li, H., Jalan-Sakrikar, N., et al. (2017). The Unfolded Protein Response Mediates Fibrogenesis and Collagen I Secretion through Regulating TANGO1 in Mice. Hepatology 65, 983–998. doi:10.1002/hep.28921
14. Moon, A. M., Singal, A. G., and Tapper, E. B. (2020). Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin. Gastroenterol. Hepatol. 18, 2650–2666. doi:10.1016/j.cgh.2019.07.060
15. Sehrawat, T. S., Liu, M., and Shah, V. H. (2020). The Knowns and Unknowns of Treatment for Alcoholic Hepatitis. Lancet Gastroenterol. Hepatol. 5, 494–506. doi:10.1016/s2468-1253(19)30326-7
16. Su, W., Wang, Y., Jia, X., Wu, W., Li, L., Tian, X., et al. (2014). Comparative Proteomic Study Reveals 17β-HSD13 as a Pathogenic Protein in Nonalcoholic Fatty Liver Disease. Proc. Natl. Acad. Sci. U.S.A. 111, 11437–11442. doi:10.1073/ pnas.1410741111
17. Xiao, J., Wang, F., Wong, N.-K., He, J., Zhang, R., Sun, R., et al. (2019). Global Liver Disease Burdens and Research Trends: Analysis from a Chinese Perspective. J. Hepatol. 71, 212–221. doi:10.1016/j.jhep.2019.03.004

18. Yin, F., Wu, M.-m., Wei, X.-l., Ren, R.-x., Liu, M.-h., Chen, C.-q., et al. (2022). Hepatic NCoR1 Deletion Exacerbates Alcohol-Induced Liver Injury in Mice by Promoting CCL2-Mediated Monocyte-Derived Macrophage Infiltration. Acta Pharmacol. Sin.. doi:10.1038/s41401-022-00863-0
19. Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., and Wymer, M. (2016). Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology 64, 73–84. doi:10.1002/hep.28431
20. Younossi, Z., Stepanova, M., Ong, J. P., Jacobson, I. M., Bugianesi, E., Duseja, A., et al. (2019). Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin. Gastroenterol. Hepatol. 17, 748–755.doi:10.1016/j.cgh.2018.05.057
21. Zeng,X.,Yuan,X.,Cai,Q.,Tang,C.,andGao,J.(2021).CircularRNAasanEpigenetic Regulator in Chronic Liver Diseases. Cells 10, 1945. doi:10.3390/cells10081945
22. Abdulla,A.,Zhang,Y.,Hsu,F.-N.,Xiaoli,A.M.,Zhao,X.,Yang,E.S.T.,etal.(2014). Regulation of Lipogenic Gene Expression by Lysine-specificHistoneDemethylase 1(LSD1). J. Biol. Chem. 289, 29937–29947. doi:10.1074/jbc.M114.573659
23. Ackerman, Z., Karmeli, F., Amir, G., and Rachmilewitz, D. (2008). Gastric and Colonic Inflammatory and Vasoactive Mediators in Experimental portal Hypertension. Liver 16, 12–18. doi:10.1111/j.1600-0676.1996.tb00697.x
24. Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., et al. (2015). Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-Term Outcomes of Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology 149, 389–397.e10. doi:10.1053/j.gastro.2015.04.043
25. Bahia, M. S., Kaur, M., Silakari, P., and Silakari, O. (2015). Interleukin-1 Receptor Associated Kinase Inhibitors: Potential Therapeutic Agents for Inflammatory and Immune-Related Disorders. Cell Signal. 27, 1039–1055. doi:10.1016/ j.cellsig.2015.02.025
26. Bracey,N.A.,Gershkovich,B.,Chun,J.,Vilaysane,A.,Meijndert,H.C.,Wright, J.R., etal. (2014).MitochondrialNLRP3 Protein Induces Reactive Oxygen Species to Promote Smad Protein Signaling and Fibrosis Independent from the Inflammasome. J. Biol. Chem. 289, 19571–19584. doi:10.1074/ jbc.M114.550624
27. Brol, M. J., Rösch, F., Schierwagen, R., Magdaleno, F., Uschner, F. E., Manekeller, S., et al. (2019). Combination of CCl4 with Alcoholic and Metabolic Injuries Mimics Human Liver Fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 317, G182–G194. doi:10.1152/ajpgi.00361.2018
28. Caballero, F., Fernández, A., Matías, N., Martínez, L., Fucho, R., Elena, M., et al. (2010). Specific Contribution of Methionine and Choline in Nutritional Nonalcoholic Steatohepatitis. J. Biol. Chem. 285, 18528–18536. doi:10.1074/ jbc.M109.099333
29. Christ, A., Günther, P., Lauterbach, M. A. R., Duewell, P., Biswas, D., Pelka, K., et al. (2018). Western Diet Triggers NLRP3-dependent Innate Immune Reprogramming. Cell 172, 162–175.e14. doi:10.1016/j.cell.2017.12.013
30. Dinarello, C. A., Simon, A., and Van Der Meer, J. W. M. (2012). Treating Inflammation by Blocking Interleukin-1 in a Broad Spectrum of Diseases. Nat. Rev. Drug Discov. 11, 633–652. doi:10.1038/nrd3800
31. Duewell,P.,Kono,H.,Rayner,K.J.,Sirois,C.M.,Vladimer,G.,Bauernfeind,F.G.,etal. (2010). NLRP3 Inflammasomes Are Required for Atherogenesis and Activated by Cholesterol Crystals. Nature 464, 1357–1361. doi:10.1038/nature08938
32. Ganz, M., Bukong, T. N., Csak, T., Saha, B., Park, J.-K., Ambade, A., et al. (2015). Progression of Non-alcoholic Steatosis to Steatohepatitis and Fibrosis Parallels Cumulative Accumulation of Danger Signals that Promote Inflammation and Liver Tumors in a High Fat-Cholesterol-Sugar Diet Model in Mice. J. Transl. Med. 13, 193. doi:10.1186/s12967-015-0552-7
33. Granzow, M., Schierwagen, R., Klein, S., Kowallick, B., Huss, S., Linhart, M., et al. (2014). Angiotensin-II Type 1 Receptor-Mediated Janus Kinase 2 Activation Induces Liver Fibrosis. Hepatology 60, 334–348. doi:10.1002/hep.27117
34. Harja, E., Bu, D.-x., Hudson, B. I., Chang, J. S., Shen, X., Hallam, K., et al. (2008). Vascular and Inflammatory Stresses Mediate Atherosclerosis via RAGE and its Ligands in apoE-/- Mice. J. Clin. Invest. 118, 183–194. doi:10.1172/JCI32703
35. Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., et al. (2012). Inflammasome-mediated Dysbiosis Regulates Progression of NAFLD and Obesity. Nature 482, 179–185. doi:10.1038/nature10809

36. Ioannou, G. N., Haigh, W. G., Thorning, D., and Savard, C. (2013). Hepatic Cholesterol Crystals and crown-like Structures Distinguish NASH from Simple Steatosis. J. Lipid Res. 54, 1326–1334. doi:10.1194/jlr.M034876
37. Jiang, H., He, H., Chen, Y., Huang, W., Cheng, J., Ye, J., et al. (2017). Identification of a Selective and Direct NLRP3 Inhibitor to Treat Inflammatory Disorders. J. Exp. Med. 214, 3219–3238. doi:10.1084/jem.20171419
38. Kleiner,D.E.,Brunt,E.M.,VanNatta,M.,Behling,C.,Contos,M.J.,Cummings,O.W., et al. (2005). Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease. Hepatology 41, 1313–1321. doi:10.1002/hep.20701
39. Larter, C. Z., and Yeh, M. M. (2008). Animal Models of NASH: Getting Both Pathology and Metabolic Context Right. J. Gastroenterol. Hepatol. 23, 1635–1648. doi:10.1111/j.1440-1746.2008.05543.x
40. Macaluso, F. S., Maida, M., and Petta, S. (2015). Genetic Background in Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Wjg 21, 11088–11111. doi:10.3748/wjg.v21.i39.11088
41. Mangan, M.S.J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., and Latz, E. (2018). Targeting the NLRP3 Inflammasome in Inflammatory Diseases. Nat. Rev. Drug Discov. 17, 588–606. doi:10.1038/nrd.2018.97
42. Martinon, F., Burns, K., and Tschopp, J. (2002). The Inflammasome. Mol. Cel 10, 417–426. doi:10.1016/S1097-2765(02)00599-3
43. Mehta, R., Neupane, A., Wang, L., Goodman, Z.,Baranova, A., and Younossi, Z. M. (2014). Expression of NALPs in Adipose and the Fibrotic Progression of Non alcoholic Fatty Liver Disease in Obese Subjects. BMC Gastroenterol. 14, 208. doi:10.1186/s12876-014-0208-8
44. SsMridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., et al. (2017). NLRP3 Inflammasome Blockade Reduces Liver Inflammation and Fibrosis in Experimental NASH in Mice. J. Hepatol. 66, 1037–1046. doi:10.1016/j.jhep.2017.01.022